An intravascular MRI contrast agent based on Gd(DO3A-Lys) for tumor angiography

Biomaterials

Volumn 35, Issue 1, 2014, Pages 327-336

  Yang, Chang Tong ^a   Chandrasekharan, Prashant ^a   He, Tao ^b   Poh, Zihan ^a   Raju, Anandhkumar ^a   Chuang, Kai Hsiang ^a,c   Robins, Edward G ^a,c  

^a AGENCY FOR SCIENCE   (Singapore)

^b INSTITUTE OF CHEMICAL AND ENGINEERING SCIENCES   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Contrast agent; Gadolinium chelate; Magnetic resonance imaging (MRI); Molecular imaging; Tumor angiography

Indexed keywords

ANGIOGRAPHY; BLOOD; MAGNETIC RESONANCE IMAGING; MAMMALS; MOLECULAR IMAGING; TOXICITY; TUMORS;

CONTRAST AGENT; CONTRAST-ENHANCED MR; GADOLINIUM CHELATES; LOW CYTOTOXICITIES; MICROENVIRONMENTS; MRI CONTRAST AGENTS; PREPARATION PROCEDURES; REPRODUCIBILITIES;

GADOLINIUM COMPOUNDS;

ALBUMIN; CONTRAST MEDIUM; GADOLINIUM [2,2',2'' [10 [3 (5 BENZAMIDO 6 METHOXY 6 OXOHEXYLAMINO) 3 OXOPROPYL] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7 TRIYL]TRIACETATE]; GALLIUM 68; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY PARENCHYMA; LIVER; MAGNETIC FIELD; MAGNETIC RESONANCE ANGIOGRAPHY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REPRODUCIBILITY; TUMOR XENOGRAFT;

MUS;

CONTRAST AGENT; GADOLINIUM CHELATE; MAGNETIC RESONANCE IMAGING (MRI); MOLECULAR IMAGING; TUMOR ANGIOGRAPHY;

ANGIOGRAPHY; ANIMALS; CONTRAST MEDIA; FEMALE; GADOLINIUM; HALF-LIFE; HETEROCYCLIC COMPOUNDS; HUMANS; LYSINE; MAGNETIC RESONANCE IMAGING; MICE; MICE, SCID; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; TISSUE DISTRIBUTION;

EID: 84887019854     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.10.006     Document Type: Article

References (37)

1. Caravan P., Ellison J.J., McMurry T.J., Lauffer R.B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics and applications. Chem Rev 1999, 99:2293-2352.
2. Aime S., Botta M., Terreno E. Gd(III)-based contrast agents for MRI. Adv Inorg Chem 2005, 57:173-237.
3. Caravan P. Strategies for increase the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006, 35:512-523.
4. Aime S., Crich S., Gianolio E., Giovenzana G., Tei L., Terreno E. High sensitivity lanthanide(III) based probes for MR-medical imaging. Coord Chem Rev 2006, 250:1562-1579.
5. Yang C.-T., Chuang K.-H. Gd(III) chelates for MRI contrast agents: from high relaxivity to "smart", from blood pool to blood-brain barrier permeable. MedChemComm 2012, 3:552-565.
6. Caravan P., Parigi G., Chasse J.M., Cloutier N.J., Ellison J.J., Lauffer R.B., et al. Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem 2007, 46:6632-6639.
7. Fink C., Goyen M., Lotz J. Magnetic resonance angiography with blood-pool contrast agents: future applications. Eur Radiol 2007, (Suppl.2):B38-B44.
8. Cavagna F.M., Lorusso V., Anelli P.L., Maggioni F., de Haën C. Preclinical profile and clinical potential of gadocoletic acid trisodium salt (B22956/1), a new intravascular contrast medium for MRI. Acad Radiol 2002, 9(Suppl.2):S491-S494.
9. Preda A., Novikov V., Möglich M., Turetschek K., Shames D.M., Brasch R.C., et al. Gadocoletic acid trisodium salt (B22956/1): a new blood pool magnetic resonance contrast agent with application in coronary angiography. Invest Radiol 2006, 41:279-291.
10. Kobayashi H., Kawamoto S., Jo S.K., Bryant H.L., Brechbiel M.W., Star R.A. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem 2003, 14:388-394.
11. Wang S.J., Brechbiel M., Wiener E.C. Characteristics of a new MRI contrast agent prepared from polypropyleneimine dendrimers, generation 2. Invest Radiol 2003, 38:662-668.
12. Helbich T.H., Gossman A., Mareski P.A., Radüchel B., Roberts T.P., Shames D.M., et al. Anew polysaccharide macromolecular contrast agent for MR imaging: biodistribution and imaging characteristics. JMagn Reson Imaging 2000, 11:694-701.
13. Tan M., Wu X., Jeong E.-K., Chen Q., Lu Z.-R. Peptide-targeted nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging. Biomacromolecules 2010, 11:754-761.
14. x)A, a new MRI contrast agent targeted to inflammation. Bioconjug Chem 2004, 15:99-103.
15. Park J.-A., Lee J.-J., Jung J.-C., Yu D.-Y., Oh C., Ha S., et al. Gd-DOTA conjugate of RGD as potential tumor-targeting MRI contrast agent. ChemBioChem 2008, 9:2811-2813.
16. Stefania R., Tei L., Barge A., Crich S.G., Szabo I., Cabella C., et al. Tuning glutamine binding modes in Gd-DOTA-based probes for an improved MRI visualization of tumor cells. Chem Eur J 2009, 15:76-85.
17. Corat C., Robert P., Lancelt E., Prigent P., Ballet S., Guilberi I., et al. Tumor imaging using P866, a high-relaxivity gadolinium chelate designed for folate receptor targeting. Magn Reson Med 2008, 60:1337-1346.
18. Chandrasekaran P., Yong C.-X., Poh Z., He T., He Z., Liu S., et al. Gadolinium chelate with DO3A conjugated 2-(diphenylphosphoryl)-ethyldiphenylphosphonium cation as potential tumor-selective MRI contrast agent. Biomaterials 2012, 33:9225-9231.
19. Lauffer R.B., Parmelee D.J., Dunham S.U., Ouellet H.S., Dolan R.P., Witte S., et al. MS-325: albumin-targeted contrast agent for MR angiography. Radiology 1998, 207:529-538.
20. Faccioli N., Marzola P., Boschi F., Sbarbati A., D'Onofrio M., Pozzi Mucelli R. Pathological animal models in the experimental evaluation of tumor microvasculature with magnetic resonance imaging. Radiol Med 2007, 112:319-328.
21. Goyen M., Shamsi K., Schoenberg S.O. Vasovist-enhanced MR angiography. European Radiol 2006, 16(Suppl.2):B9-B14.
22. Majos A., Wolak T., Bogorodzki P., Tybor K., Sapieha M., Stefańczyk L. Ablood pool contrast aided T1 functional MRI in patients with brain tumors-a preliminary study. Neuroradiology 2011, 53:523-531.
23. Essig M., Rohrer M., Giesel F., Tüttenberg J., Weber M.A., Michaely H., et al. Human brain tumor imaging with a protein-binding MR contrast agent: initial experience. Eur Radiol 2010, 20:218-226.
24. Kittigowittana K., Yang C.-T., Cheah W.C., Tuang C.Y., Chang Y.-T., Chuang K.-H., et al. Development of novel intravascular contrast agents for MRI using gadolinium chelates. ChemMedChem 2011, 6:781-787.
25. * relaxivities of human whole blood to prohance, vasovist, and deoxyhemoglobin. Magn Reson Med 2008, 60:1313-1320.
26. Bogdanov A.A., Lewin M.T., Weissleder R. Approaches and agents for imaging the vascular system. Adv Drug Deliv Rev 1999, 37:279-293.
27. Leiner T., Goyen M., Rohren M., Schönberg S. Clinical blood pool MR imaging 2008, Springer.
28. Lauffer R.B. Targeted relaxation enhancement agents for MRI. Magn Reson Med 1991, 22:339-342.
29. Caravan P., Cloutier N.J., Greenfield M.T., McDermid S.A., Dunham S.U., Bulte J.W., et al. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. JAm Chem Soc 2002, 124:3152-3162.
30. Steger-Hartmann T., Graham P.B., Müller S., Schweinfurth H. Preclinical safety assessment of vasovist (Gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography. Invest Radiol 2006, 41:449-459.
31. Soltys R.A. Summary of preclinical safety evaluation of gadoteridol injection. Invest Radiol 1992, 27:S7-S11.
32. Döhr O., Hofmeister R., Treher M., Schweinfurth H. Preclinical safety evaluation of Gd-EOB-DTPA (Primovist). Invest Radiol 2007, 42:830-841.
33. Barrett T., Brechbiel M., Bernardo M., Choyke P.L. MRI of tumor angiogenesis. JMagn Reson Imaging 2007, 26:235-249.
34. Türkbey B., Thomasson D., Pang Y., Bernardo M., Choyke P.L. The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment. Diagn Interv Radiol 2010, 16:186-192.
35. Hara N., Okuizumi M., Koike H., Kawaguchi M., Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. The Prostate 2005, 62:140-147.
36. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583-592.
37. Bellin M.F., Vasile M. Morel-Precetti. Currently used non-specific extracellular MR contra media. Eur Radiol 2003, 13:2688-2698.